Protocol Ledger

NCT07412470 · Phase II/III · RECRUITING

A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

Interventional Phase II/III clinical trial protocol NCT07412470 sponsored by Sanofi in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-03-13 Enrollment: 526 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07412470
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)526 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07412470
Protocol FieldVerified Registry Value
NCT IdentifierNCT07412470
Consolidated Lead SponsorSanofi
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment526 participants (ESTIMATED)
Registered Start Date2026-03-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Sanofi across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI